Product information and disease description
Place of product in therapy
310 evidence topics · 104 sources
Tovorafenib (DAY101)
RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
- Manufacturer
- Day One Biopharmaceuticals
- Regulatory submission
- Not announced
- Launch
- Not announced
- Last updated